Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934749 | 1.00 | UMPS (0.48) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL7893929 | 0.86 | UMPS (0.54) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL3810818 | 0.85 | KDM4E (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL30669424 | 0.83 | KDM4E (0.42) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL1980709 | 0.82 | UMPS (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL27596793 | 0.82 | UMPS (0.44) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL5547964 | 0.82 | UMPS (0.54) | UMPS | |
| SCHEMBL218016 | 0.81 | UMPS (0.54) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL8493435 | 0.80 | ADORA2A (0.34) | UMPSKDM4EMAPTBLMSMN1; SMN2 | |
| SCHEMBL8498082 | 0.80 | ADORA2A (0.36) | UMPSKDM4EMAPTBLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 983 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582626-B2 | Methods and compositions for treating cancer | The Wister Institute of Anatomy and Biology (US) | 2026-03-24 | — | — | US | claimed |
| EP-4582090-A2 | COMPOSITION COMPRISING PEGYLATED ARGININE DEIMINASE | Polaris Group (TW) | 2025-07-09 | — | — | EP | claimed |
| EP-3782653-B1 | COMPOSITION COMPRISING PEGYLATED ARGININE DEIMINASE | POLARIS GROUP (TW) | 2025-03-19 | — | — | EP | claimed |
| US-20240415786-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | NESTLE SA (CH) | 2024-12-19 | — | — | US | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| EP-4422423-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2024-09-04 | — | — | EP | claimed |
| US-20240075050-A1 | Methods and Compositions for Treating Leucine Rich Repeat Kinase 2 (LRRK2)-Associated Disorder or Condition | UNIVERSITY OF CONNECTICUT (US) | 2024-03-07 | — | — | US | claimed |
| US-20240041767-A1 | Mitochondria-Enriched Extracellular Vesicles | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2024-02-08 | — | — | US | claimed |
| WO-2023073054-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2023-05-04 | — | — | WO | claimed |
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| US-20060160751-A1 | 5-Amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-07-20 | — | — | US | claimed |
| WO-2006074416-A1 | 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE AND ITS NUCLEOBASE AS POTENTIATORS OF ANTIFOLATE TRANSPORT AND METABOLISM | HEALTH RESEARCH INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20050002943-A1 | Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2005-01-06 | — | — | US | claimed |
| EP-1492564-A2 | AMP-KINASE AGONISTS OR ADENOSINE PRO-DRUGS AS IMMUNO-STIMULATING AGENTS | Université Libre de Bruxelles (BE) | 2005-01-05 | — | — | EP | claimed |
| US-20030212013-A1 | Use of amp kinase activators for treatment type 2 diabetes and insulin resistance | BRIGHAM YOUNG UNIVERSITY | 2003-11-13 | — | — | US | claimed |
| WO-2003037371-A2 | AMP-KINASE AGONISTS OR ADENOSINE PRO-DRUGS AS IMMUNO-STIMULATING AGENTS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2003-05-08 | — | — | WO | claimed |
| WO-2001097816-A1 | USE OF AMP KINASE ACTIVATORS FOR TREATMENT OF TYPE 2 DIABETES AND INSULIN RESISTANCE | BRIGHAM YOUNG UNIVERSITY (US) | 2001-12-27 | — | — | WO | claimed |
| US-RE34387-E | Method for restoring depleted purine nucleotide pools | DUKE UNIVERSITY (US) | 1993-09-21 | — | — | US | claimed |
| US-5082829-A | 5-amino-4-imidazolecarboxamide riboside to increase adenosine concentration, cardiovascular, seizures | GENSIA PHARMACEUTICALS (US) | 1992-01-21 | — | — | US | claimed |
| US-4575498-A | 5-AMINO-4-IMIDAZOLE CARBOXAMIDE RIBOSIDE | DUKE UNIVERSITY (US) | 1986-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582626-B2 | Methods and compositions for treating cancer | ICOS, PPARD, CD69 | UMPS 4089/4885KDM4E 1151/4885MAPT 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.